Kanamycin Acid Sulfate (CAS No.: 70560-51-9) - Aminoglycoside Antibacterial for Gram-Negative & Drug-Resistant Infections

As a professional supplier of pharmaceutical-grade and veterinary-grade antibacterial active ingredients, we provide high-purity Kanamycin Acid Sulfate that strictly complies with global pharmacopoeia standards (USP, EP, BP, CP). A natural aminoglycoside antibiotic derived from Streptomyces kanamyceticus, it exhibits potent bactericidal activity against a broad range of Gram-negative bacteria and select Gram-positive pathogens. It is widely used in human medicine for treating severe infections (e.g., urinary tract, respiratory, and systemic infections) and in veterinary practice for livestock and companion animals-serving as a critical agent against susceptible and drug-resistant strains.

Product Basic Information

Core Functions & Mechanism of Action

CAS#70560-51-9 exerts a bactericidal effect by targeting the bacterial ribosome, disrupting protein synthesis-a mechanism characteristic of aminoglycoside antibiotics:

Ribosome Binding: Kanamycin binds irreversibly to the 30S subunit of the bacterial ribosome, specifically interacting with the 16S rRNA.

Protein Synthesis Disruption: This binding blocks two critical steps:

The initiation of protein synthesis (prevents formation of the ribosome-mRNA-tRNA complex).

The accurate reading of mRNA codons (causes misincorporation of amino acids into newly synthesized proteins).

Bacterial Death: Accumulation of non-functional, toxic proteins damages the bacterial cell membrane, leading to osmotic lysis and cell death.

Key antibacterial spectrum advantages:

Gram-Negative Coverage: Active against common pathogens like Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter spp., and Salmonella spp.-including some strains resistant to penicillins or cephalosporins.

Gram-Positive Coverage: Inhibits susceptible Staphylococcus aureus (MSSA) and Streptococcus spp. (though not first-line for these pathogens).

Core Applications

Kanamycin Acid Sulfate CAS#70560-51-9 is administered parenterally (IV, IM) or topically (ophthalmic, otic) in humans (oral absorption is poor); in veterinary use, it is also used in oral formulations for gastrointestinal infections. It is reserved for moderate-to-severe bacterial infections where other antibiotics are ineffective or contraindicated.

1. Human Pharmaceutical Field

1.1 Systemic Infections

Septicemia & Bacteremia: Treats bloodstream infections caused by susceptible Gram-negative bacteria (e.g., E. coli, K. pneumoniae). IV/IM dose: 15–30 mg/kg/day (divided into 2–3 doses) for 7–14 days, adjusted for renal function.

Urinary Tract Infections (UTIs): For complicated UTIs resistant to first-line antibiotics. IV/IM dose: 15–30 mg/kg/day for 7–10 days.

Respiratory Tract Infections (RTIs): Treats hospital-acquired pneumonia (HAP) caused by susceptible Pseudomonas aeruginosa or Acinetobacter spp. IV dose: 15–30 mg/kg/day for 10–14 days.

1.2 Topical Infections

Ophthalmic Infections: Formulated as eye drops/ointments for bacterial conjunctivitis or keratitis caused by Staphylococcus aureus or Haemophilus influenzae (0.5% concentration, 1–2 drops every 4 hours).

Otic Infections: Used in ear drops for bacterial otitis externa (combined with hydrocortisone to reduce inflammation, 0.3% concentration, 3–4 drops daily).

1.3 Other Uses

Intestinal Sterilization: Oral formulations (not absorbed systemically) for pre-surgical bowel preparation to reduce Gram-negative flora (1–2 g/day for 2–3 days).

Tuberculosis (TB): Second-line agent for drug-resistant TB (combined with other anti-TB drugs, 15 mg/kg/day for 6–12 months).

2. Veterinary Field (Livestock & Companion Animals)

CAS#70560-51-9 is used to treat bacterial infections in cattle, pigs, chickens, dogs, and cats:

Bovine Respiratory Disease (BRD): Caused by susceptible Mannheimia haemolytica or Pasteurella multocida. IM dose: 10–15 mg/kg body weight once daily for 3–5 days.

Porcine Diarrhea: For E. coli-induced scours in piglets. Oral/IM dose: 10–20 mg/kg once daily for 3–5 days.

Poultry Colibacillosis: Treats E. coli infections in chickens. Oral dose: 20–40 mg/kg feed or drinking water for 5–7 days.

Canine/Feline UTIs & Skin Infections: For susceptible E. coli (UTIs) or Staphylococcus pseudintermedius (skin). IM dose: 5–10 mg/kg twice daily for 7–14 days.

Contraindications: Avoid use in neonates (nephrotoxicity risk) or animals with pre-existing renal impairment; not approved for dairy cattle producing milk for human consumption.

Quality & Safety Assurance

As an aminoglycoside with a narrow therapeutic index (risk of nephrotoxicity and ototoxicity),  requires rigorous quality control to ensure potency, purity, and safety:

1. Manufacturing & Purity Control

Production: Produced via microbial fermentation of Streptomyces kanamyceticus, followed by purification (ion-exchange chromatography) and acid sulfate salt formation. The process ensures:

Minimal impurities (e.g., related aminoglycosides, fermentation byproducts) ≤2.0% (pharmaceutical grade);

Consistent sulfate content (18.0%–22.0%), critical for uniform potency.

GMP Compliance: Pharmaceutical-grade Kanamycin Acid Sulfate CAS#70560-51-9 is manufactured in Grade C/D cleanrooms (per ICH Q7 guidelines) for injectable use, with strict control over endotoxin levels (≤0.5 EU/mg) to avoid sepsis.

2. Comprehensive Testing Protocol

3. Safety Reminders

Human Use:

Contraindications: Hypersensitivity to aminoglycosides; severe renal impairment (CrCl <30 mL/min); pre-existing hearing loss or tinnitus (ototoxicity risk); myasthenia gravis (neuromuscular blockade risk).

Adverse Effects: Dose-dependent nephrotoxicity (monitor serum creatinine, BUN) and ototoxicity (monitor hearing/vestibular function); rare but serious: neuromuscular paralysis (treat with calcium gluconate).

Therapeutic Drug Monitoring (TDM): Required for patients with renal impairment or prolonged therapy-target peak concentration 20–30 μg/mL, trough concentration <10 μg/mL.

Veterinary Use:

Withdrawal Periods: Cattle: 28 days (meat); Pigs: 21 days (meat); Chickens: 7 days (meat/eggs); Dogs/Cats: No withdrawal period (non-food animals).

Residue Warning: Prohibited in dairy cattle (milk residues) and laying hens (egg residues) beyond the withdrawal period.

Cooperation & Contact

We supply Kanamycin Acid Sulfate CAS#70560-51-9 in grades tailored to human and veterinary applications:

Pharmaceutical Grade: Fine powder for injectable/topical formulations (1kg–100kg per order, sealed aluminum foil bags with desiccants).

Veterinary Grade: Powder for livestock oral premixes or injectables (10kg–500kg per order; monthly production capacity of 2000kg).

Value-added services include:

Providing DMF (Drug Master File) and CEP (Certificate of Suitability) for pharmaceutical-grade products to support EU/US/Asia registration.

Technical support for TDM protocols (human use) and veterinary formulation stability testing (e.g., oral premixes, injectables).

Batch-specific COA with endotoxin, purity, and assay results to ensure regulatory compliance.

If you are a pharmaceutical manufacturer, hospital supplier, or veterinary drug enterprise, please contact us for detailed cooperation:

Contact Information:

Email: sales@huarongpharma.com

Phone/WhatsApp: +86 13751168070

We adhere to the principles of "antibacterial efficacy, safety compliance, and resistance management" and look forward to partnering with global healthcare and animal health industries!

Hot Tags: kanamycin acid sulfate cas#70560-51-9, China kanamycin acid sulfate cas#70560-51-9 manufacturers, suppliers, api for business intelligence, api for e commerce, api for logistics, api for social media marketing, api for targeting, api reliability